By Yafo Life Sciences
December 27th, 2021 (Shanghai) — We are glad to announce that Richard Yu, the General Manager of the I&BD Department of Huadong Medicine(华东医药), has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
Speech Topic: Chinese Large-cap Pharma License-in/out Strategy-Huadong Medicine Perspectives
演讲题目：中国大型药企license-in/out的交易策略 – 华东医药视角
About the speaker
Richard Yu joins Huadong Medicine on January 1st, 2020, as the General Manager of the Investment and BD Department of Huadong Medicine, he is mainly responsible for the license-in and investment of innovative drugs, as well as the fastening and accelerating of the transformation of Huadong Medicine through investment and product license-in.
Before joinging Huadong, he served as the BD Director of UCB and Sanofi, as well as the Director of Alliance Management of Xi’an Janssen Pharmaceutical and Deputy President of Harbour BioMed, dedicated to the Pharmaceutical investment. Richard Yu has over 20 years of experience of Pharmaceutical Investment.
专家简介：
余熹先生2020年1月1日加入华东医药股份有限公司，现任华东医药股份有限公司投资总经理，负责华东医药创新产品引进与投资，致力于通过投资和产品引进的方式加速和推动华东医药创新转型。
加入华东医药之前余熹先生曾任优时比制药有限公司业务发展总监，杨森制药有限公司联盟管理总监，赛诺菲BD总监以及和铂医药BD副总裁。专注药物投资和发展领域多年拥有超过20年医药投资相关经验。
About Huadong Medicine
Huadong Medicine (stock code: 000963) was founded in 1993, and is headquartered in Hangzhou, Zhejiang. It was listed on the Shenzhen Stock Exchange in December 1999. The company’s business covers pharmaceutical industry, pharmaceutical business and medical aesthetics industry.It has developed into a large-scale comprehensive pharmaceutical company integrating research and development, production and distribution. Huadong Medicine is the 17th largest pharmaceutical company in China. In 2020, the company’s annual sales revenue of 5 billion USD. Key therapeutic areas include oncology, immunology, diabetes and nephrology.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
If you are interested in listening to the live event, please register at https://biotochina.org/register/
Contact US
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 